Pharma Pulse 2/14/25: Building Confidence in CGT Innovation, The Power of PBMs and Biosimilars & more

Building Confidence in CGT Innovation

In the fourth part of her video interview with Pharma Commerce Editor Nicholas Saraceno, Jenna Dale, director of client relations at Cencora, explains the value of FDA guidance documents for manufacturers, along with the areas of CGT development that would benefit most from standardization.

The Power of PBMs and Biosimilars, 2025 Launches of the Stelara Biosimilars, the IRA and Interchangeability | Q&A with Craig Burton, MBA

The second part of our conversation with Craig Burton, MBA, executive director of the Biosimilars Council, a trade and lobbying group for the biosimilars industry.

Robert F. Kennedy Jr. Confirmed as HHS Secretary

Kennedy was confirmed by a mostly party-line vote in the Senate.

Angels for Change Launches Project GOLD

Angels for Change (A4C) announces the pilot launch of Project GOLD (Generic Oncology Lifesaving Drugs), a new resiliency program that establishes an onshore buffer supply of six essential medications that are used to treat cancer. Project GOLD was created to offer physicians and patients stability of care during a shortage through emergency supply at leading distributors and manufacturers. A4C is participating with founding pilot members, pharmaceutical wholesalers Cencora and McKesson, and pharmaceutical and medtech manufacturer Fresenius Kabi, highlighting the power of collaboration in addressing this critical issue.

Ian Baer on LinkedIn

If over 80% of all social sharing occurs privately, how can brands (whether in or outside of the healthcare sector) take advantage of this? We discuss the topic in the fourth part of my conversation with Miranda Schmalfuhs from Pharmaceutical Executive. And be sure to catch the full interview next week!

Have news you want us to share in Pharma Pulse? Reach out to Editor Miranda Schmalfuhs